Amgen, Inc. (AMGN)
Amgen's Tavneos faces renewed scrutiny in Europe, while competitors Eli Lilly and Novo Nordisk advance with MASH treatments, impacting market dynamics.
About Amgen, Inc.
Amgen, Inc. is a biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics.
Amgen, Inc. uses the ticker $AMGN for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Amgen, Inc. entered the top [--] AltRank™ for the first time
Price: $369.20
Price 24-Hour Time-Series Raw Data
Amgen's price has surged to a 52-week and all-time high, fueled by positive social media trends, increased engagement, and strong Q4 earnings reports that exceeded expectations and provided optimistic future guidance.
24-Hour: 1.8% 7-Day: -3.6% 30-Day: 11.74%
1-Year High: $384.30 on 2026-02-06
1-Year Low: $262.30 on 2025-05-14
AltRank: [---]
AltRank 24-Hour Time-Series Raw Data
Amgen, Inc. (AMGN) is currently AltRank #257 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [---] [----]
[--] Month: [---] [----]
[--] Months: [---] [----]
[--] Year: [---] [---]
1-Year High: [-----] on 2025-04-19
1-Year Low: [--] on 2025-02-24
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2025-05-27
1-Year Low: [--] on 2025-06-25
Engagements: [------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [-------]
[--] Week: [-------] -71%
[--] Month: [---------] -42%
[--] Months: [----------] +63%
[--] Year: [----------] -30%
1-Year High: [---------] on 2025-09-07
1-Year Low: [------] on 2026-01-18
Engagements by network (24h): News: [--] Instagram: [-----] YouTube: [-----] X: [------] TikTok: [-----] Reddit: [---]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Week: [-----] -9.80%
[--] Month: [-----] +63%
[--] Months: [------] +16%
[--] Year: [------] +14%
1-Year High: [-----] on 2025-08-16
1-Year Low: [---] on 2025-12-07
Mentions by network (24h): News: [--] Instagram: [--] YouTube: [--] X: [---] TikTok: [--] Reddit: [--]
Creators: [---] (24h)
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning Amgen, Inc. (AMGN) in the last [--] hours which is down 23% from [---] in the previous [--] hours
Daily Average: [---]
[--] Week: [-----] -17%
[--] Month: [-----] +56%
[--] Months: [-----] +38%
[--] Year: [------] +92%
1-Year High: [---] on 2025-06-27
1-Year Low: [---] on 2025-12-06
The most influential creators that mention Amgen, Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @semodough | [--] | [-----] | [--] | [-----] |
| @tunemusicalmoments | [--] | [---------] | [--] | [-----] |
| @HOThomasWPhelps | [--] | [-----] | [--] | [-----] |
| @USAmbJapan | [--] | [-------] | [--] | [---] |
| @amgen | [--] | [------] | [--] | [---] |
| @CJsCalls | [--] | [-----] | [--] | [---] |
| @eWhispers | [--] | [-------] | [--] | [---] |
| @financebully | [--] | [-----] | [--] | [---] |
| @SENefrologia | [--] | [------] | [--] | [---] |
| @Dykegail | [--] | [--] | [--] | [---] |
Sentiment: 87%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 87%
Daily Average: 79%
[--] Week: 75% -19%
[--] Month: 83% +11%
[--] Months: 83% +9%
[--] Year: 83% +8%
1-Year High: 97% on 2025-12-30
1-Year Low: 53% on 2025-04-13
Most Supportive Themes:
- Amgen's Galaxy Score and Social Dominance Surge: (40%) Amgen's Galaxy Score has reached a near 52-week high, indicating strong overall performance. Social dominance has also seen a significant increase, suggesting growing online presence and influence.
- Increased Engagement and Post Activity: (35%) There has been a substantial rise in engagements and posts created for Amgen, indicating heightened community interaction and content generation.
- Positive Sentiment and Market Cap Growth: (25%) Sentiment surrounding Amgen is overwhelmingly positive, and its market capitalization has shown consistent growth over the past year.
Most Critical Themes:
- Market Dominance Near 52-Week Low: (60%) Amgen's market dominance is currently near its 52-week low, suggesting a potential decrease in its share of market attention relative to competitors.
- AltRank Decline: (40%) Amgen's AltRank has seen a significant decrease over the past month and year, indicating a lower ranking in combined social and market metrics.
Social Dominance: 0.039%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.039%
Daily Average: 0.087%
[--] Week: 0.044% -0.00030000000000000165%
[--] Month: 0.067% -0.0021%
[--] Months: 0.067% -0.057%
[--] Year: 0.067% -0.033%
1-Year High: 0.194% on 2025-03-12
1-Year Low: 0.035% on 2025-12-06
Market Dominance: 0.225%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.225%
Daily Average: 0%
1-Year High: 0.331% on 2025-03-12
1-Year Low: 0.18% on 2025-09-25
Market Cap: $198,971,850,000
Market Cap 24-Hour Time-Series Raw Data
Current Value: $198,971,850,000
Daily Average: $163,965,761,515
[--] Week: $198,971,850,000 -3.60%
[--] Month: $198,993,410,000 +12%
[--] Months: $198,993,410,000 +25%
[--] Year: $198,993,410,000 +27%
1-Year High: $207,148,480,000 on 2026-02-06
1-Year Low: $141,029,560,629 on 2025-05-14
Top Amgen, Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$NVO CHMP MASH EU Kayshild . $LLY Mounjaro $AMGN Tavneos . (MASH) . $NVO moved closer to EU approval for semaglutide in MASH after a positive CHMP opinion with plans to market it under the new brand Kayshild. At the same time $LLY did not secure a new cardiovascular label expansion for Mounjaro while $AMGN faces renewed scrutiny of Tavneos $NVO moved closer to EU approval for semaglutide in MASH after a positive CHMP opinion with plans to market it under the new brand Kayshild. At the same time $LLY did not secure a new cardiovascular label expansion for Mounjaro while"
X Link @leodore_kor 2026-02-16T08:28Z [---] followers, [---] engagements
"$NVO moved closer to EU approval for semaglutide in MASH after a positive CHMP opinion with plans to market it under the new brand Kayshild. At the same time $LLY did not secure a new cardiovascular label expansion for Mounjaro while $AMGN faces renewed scrutiny of Tavneos data in Europe. If confirmed by the European Commission semaglutide would expand further beyond obesity and diabetes into MASH a field with limited treatment options. Link to article: #StocksToWatch #investing https://patientworthy.com/2026/02/15/chmp-backs-novo-nordisks-semaglutide-for-mash-opening-door-to-eu-approval/"
X Link @investseekers 2026-02-16T08:20Z [----] followers, [----] engagements
"Lilly vs. Novo isn't over. Oral versions of GLP-1 drugs are the next $100B frontier. Supply chains are finally easing but insurance hurdles and compounding manufacturing costs remain the primary bear case for [----]. Data is king here. $LLY $NVO $VKTX $AMGN $ALT $MRK"
X Link @MartinezX631 2026-02-16T01:55Z [---] followers, [---] engagements
"Hey Jack great write-up on $ABCL as always. Thank you so much. Quick question have you thought about the GLP-1/obesity optionality for AbCellera's GPCR platform GLP-1R is a Class B GPCR. Amgen is already validating antibody-based GPCR targeting in this space with MariTide (anti-GIPR antibody + GLP-1 peptides) showing 20% weight loss at [--] weeks with monthly dosing. If [---] validates the GPCR platform the optionality goes way beyond hot flashes. Nobody knows if AbCellera will ever touch this space but just curious if it's something you've thought about."
X Link @iamrocketmen 2026-02-16T00:56Z 16.5K followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing